Breast Cancer Articles | Page 2

FDA Approves Stereotactic Radiotherapy System for Breast Cancer
The FDA has approved a new breast-specific stereotactic body radiotherapy device known as GammaPod as a treatment for patients with breast cancer, based on findings from a 17-patient study.
NICE Recommends Approval for Ribociclib, Palbociclib for HR+/ HER2- Advanced Breast Cancer
The United Kingdom's National Institute for Health and Care Excellence has issued guidance supporting approval for ribociclib and palbociclib for patients with hormone receptor-positive/HER2-negative locally advanced or secondary breast cancer.
FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer
The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.
CDK4/6 Inhibitors Make Impact in HR-Positive Metastatic Breast Cancer
The introduction of cyclin-dependent kinase 4/6 inhibitors has resulted in a significant paradigm shift in the treatment of hormone receptor–positive breast cancer, helping to make the new agents part of rapidly developing improvements in personalized care for patients.
The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
Precision Medicine a Necessary Component in HER2+ Breast Cancer Care
Mothaffar Fahed Rimawi, MD, discusses the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.
Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,
Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer
The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer. 
Antibody-Drug Conjugate Active in Heavily Pretreated Metastatic TNBC
Monotherapy with an antibody drug conjugate targeting the transmembrane protein LIV-1 had encouraging antitumor activity in a phase 1 study of patients with heavily pretreated TNBC.
Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide
Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.
Publication Bottom Border
Border Publication